NCT02599896View on ClinicalTrials.gov

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

July 25, 2018

Study Completion Date

July 25, 2018

Conditions
Prevention of HIV InfectionHIV AntibodiesMonoclonal Antibody, HumanNeutralizing Antibody
Interventions
BIOLOGICAL

VRC-HIVMAB080-00-AB (VRC01LS)

VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

BIOLOGICAL

VRC-HIVMAB060-00-AB (VRC01)

VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02599896 - Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults | Biotech Hunter | Biotech Hunter